Search Results - "Hepatology (Baltimore, Md.)"

A multisociety Delphi consensus statement on new fatty liver disease nomenclature by Rinella, Mary E, Lazarus, Jeffrey V, Ratziu, Vlad, Francque, Sven M, Sanyal, Arun J, Kanwal, Fasiha, Romero, Diana, Abdelmalek, Manal F, Anstee, Quentin M, Arab, Juan Pablo, Arrese, Marco, Bataller, Ramon, Beuers, Ulrich, Boursier, Jerome, Bugianesi, Elisabetta, Byrne, Christopher D, Castro Narro, Graciela E, Chowdhury, Abhijit, Cortez-Pinto, Helena, Cryer, Donna R, Cusi, Kenneth, El-Kassas, Mohamed, Klein, Samuel, Eskridge, Wayne, Fan, Jiangao, Gawrieh, Samer, Guy, Cynthia D, Harrison, Stephen A, Kim, Seung Up, Koot, Bart G, Korenjak, Marko, Kowdley, Kris V, Lacaille, Florence, Loomba, Rohit, Mitchell-Thain, Robert, Morgan, Timothy R, Powell, Elisabeth E, Roden, Michael, Romero-Gómez, Manuel, Silva, Marcelo, Singh, Shivaram Prasad, Sookoian, Silvia C, Spearman, C Wendy, Tiniakos, Dina, Valenti, Luca, Vos, Miriam B, Wong, Vincent Wai-Sun, Xanthakos, Stavra, Yilmaz, Yusuf, Younossi, Zobair, Hobbs, Ansley, Villota-Rivas, Marcela, Newsome, Philip N

“…The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This…”
Get full text

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review by Younossi, Zobair M, Golabi, Pegah, Paik, James M, Henry, Austin, Van Dongen, Catherine, Henry, Linda

“…NAFLD is a leading cause of liver-related morbidity and mortality. We assessed the global and regional prevalence, incidence, and mortality of NAFLD using an…”
Get full text

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease by Rinella, Mary E, Neuschwander-Tetri, Brent A, Siddiqui, Mohammad Shadab, Abdelmalek, Manal F, Caldwell, Stephen, Barb, Diana, Kleiner, David E, Loomba, Rohit

Get full text

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma by Singal, Amit G, Llovet, Josep M, Yarchoan, Mark, Mehta, Neil, Heimbach, Julie K, Dawson, Laura A, Jou, Janice H, Kulik, Laura M, Agopian, Vatche G, Marrero, Jorge A, Mendiratta-Lala, Mishal, Brown, Daniel B, Rilling, William S, Goyal, Lipika, Wei, Alice C, Taddei, Tamar H

Get full text

Epidemiology of Hepatocellular Carcinoma by McGlynn, Katherine A., Petrick, Jessica L., El‐Serag, Hashem B.

“…Liver cancer is a major contributor to the worldwide cancer burden. Incidence rates of this disease have increased in many countries in recent decades. As the…”
Get full text

Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis by Younossi, Zobair, Tacke, Frank, Arrese, Marco, Chander Sharma, Barjesh, Mostafa, Ibrahim, Bugianesi, Elisabetta, Wai‐Sun Wong, Vincent, Yilmaz, Yusuf, George, Jacob, Fan, Jiangao, Vos, Miriam B

“…Over the past 2 decades, nonalcoholic fatty liver disease (NAFLD) has grown from a relatively unknown disease to the most common cause of chronic liver disease…”
Get full text

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases by Marrero, Jorge A., Kulik, Laura M., Sirlin, Claude B., Zhu, Andrew X., Finn, Richard S., Abecassis, Michael M., Roberts, Lewis R., Heimbach, Julie K.

Get full text

Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases by Biggins, Scott W., Angeli, Paulo, Garcia‐Tsao, Guadalupe, Ginès, Pere, Ling, Simon C., Nadim, Mitra K., Wong, Florence, Kim, W. Ray

Get full text

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases by Chalasani, Naga, Younossi, Zobair, Lavine, Joel E., Charlton, Michael, Cusi, Kenneth, Rinella, Mary, Harrison, Stephen A., Brunt, Elizabeth M., Sanyal, Arun J.

Get full text

Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases by Mack, Cara L., Adams, David, Assis, David N., Kerkar, Nanda, Manns, Michael P., Mayo, Marlyn J., Vierling, John M., Alsawas, Mouaz, Murad, Mohammad H., Czaja, Albert J.

Get full text

AASLD guidelines for the treatment of hepatocellular carcinoma by Heimbach, Julie K., Kulik, Laura M., Finn, Richard S., Sirlin, Claude B., Abecassis, Michael M., Roberts, Lewis R., Zhu, Andrew X., Murad, M. Hassan, Marrero, Jorge A.

Get full text

Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD by Paik, James M., Golabi, Pegah, Younossi, Youssef, Mishra, Alita, Younossi, Zobair M.

“…Background and Aims Chronic hepatitis B virus (HBV), hepatitis C virus (HCV), nonalcoholic fatty liver disease (NAFLD), and alcohol‐associated liver disease…”
Get full text

Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection by Ghany, Marc G., Morgan, Timothy R.

Get full text

Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps by Lonardo, Amedeo, Nascimbeni, Fabio, Ballestri, Stefano, Fairweather, DeLisa, Win, Sanda, Than, Tin A., Abdelmalek, Manal F., Suzuki, Ayako

“…Despite tremendous research advancements in nonalcoholic fatty liver disease (NAFLD), our understanding of sex differences in NAFLD remains insufficient. This…”
Get full text

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease by Estes, Chris, Razavi, Homie, Loomba, Rohit, Younossi, Zobair, Sanyal, Arun J.

“…Nonalcoholic fatty liver disease (NAFLD) and resulting nonalcoholic steatohepatitis (NASH) are highly prevalent in the United States, where they are a growing…”
Get full text

Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases by Lai, Jennifer C., Tandon, Puneeta, Bernal, William, Tapper, Elliot B., Ekong, Udeme, Dasarathy, Srinivasan, Carey, Elizabeth J.

Get full text

RNA N6‐methyladenosine methyltransferase‐like 3 promotes liver cancer progression through YTHDF2‐dependent posttranscriptional silencing of SOCS2 by Chen, Mengnuo, Wei, Lai, Law, Cheuk‐Ting, Tsang, Felice Ho‐Ching, Shen, Jialing, Cheng, Carol Lai‐Hung, Tsang, Long‐Hin, Ho, Daniel Wai‐Hung, Chiu, David Kung‐Chun, Lee, Joyce Man‐Fong, Wong, Carmen Chak‐Lui, Ng, Irene Oi‐Lin, Wong, Chun‐Ming

“…Epigenetic alterations have contributed greatly to human carcinogenesis. Conventional epigenetic studies have predominantly focused on DNA methylation, histone…”
Get full text

Diagnosis and Treatment of Alcohol‐Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases by Crabb, David W., Im, Gene Y., Szabo, Gyongyi, Mellinger, Jessica L., Lucey, Michael R.

Get full text

The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma by Donne, Romain, Lujambio, Amaia

“…The liver is the sixth most common site of primary cancer in humans and the fourth leading cause of cancer-related death in the world. Hepatocellular carcinoma…”
Get full text

Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases by Northup, Patrick G., Garcia‐Pagan, Juan Carlos, Garcia‐Tsao, Guadalupe, Intagliata, Nicolas M., Superina, Riccardo A., Roberts, Lara N., Lisman, Ton, Valla, Dominique C.

Get full text